Endocrine Unit, Hospital Universitari de Bellvitge-IDIBELL and CIBERDEM, L'Hospitalet de Llobregat, Spain.
Educadora de Diabetes, Hospital de Elda, Alicante, Spain.
Curr Med Res Opin. 2024 Nov;40(11):1841-1846. doi: 10.1080/03007995.2024.2407960. Epub 2024 Oct 8.
To determine the preferences regarding injection, medication frequency and complexity of GLP1 receptor agonists among patients with type 2 diabetes, treatment-naïve for such drugs in Spain. Additionally, patients' willingness to pay according to these attributes was evaluated.
A discrete-choice experiment survey designed to evaluate patients' preferences over three attributes discriminating by age, sex and patients experience with previous injectable treatment was fulfilled by patients. The resulting model was analyzed using a conditional (fixed-effects) logistic regression.
A total of 180 patients (63.35 ± 11.49 years, 63.28% men, 48.41% with previous cardiovascular disease, 54.69% with a time of evolution of diabetes >10 years) recruited from 5 health care centers in Spain completed the survey. Patients viewed positively weekly injections (vs daily injections), but rated negatively a complex preparation of the dose (vs simple preparation). Whereas naïve patients for injectable medications did not consider administration timing of importance, no naïve patients considered it relevant. No relevant differences were observed according to age or gender. Patients were willing to pay 83.25€for a "no preparation required" dose. No naïve and naïve patients were willing to pay 34.61€ and 14.35€; = 0.000, to change daily injection for a weekly injection.
Patients highly valued the avoidance of injections, with weekly dosing clearly preferred over daily dosing, as well as reducing the treatment complexity. These findings may provide a better understanding of what patients prefer and value in their treatment and provide guidance for clinicians making therapeutic decisions regarding treatments of patients with type 2 diabetes.
确定西班牙初治 2 型糖尿病患者对 GLP1 受体激动剂的注射、用药频率和复杂性的偏好。此外,还评估了患者根据这些属性的支付意愿。
通过患者完成一项离散选择实验调查,评估患者对三个属性(按年龄、性别和患者之前接受过的注射治疗经验区分)的偏好。使用条件(固定效应)逻辑回归分析所得模型。
共纳入来自西班牙 5 家医疗中心的 180 名患者(63.35±11.49 岁,63.28%为男性,48.41%有心血管疾病史,54.69%糖尿病病程>10 年)完成了调查。患者对每周注射(vs 每日注射)持积极态度,但对复杂的剂量准备(vs 简单的剂量准备)评价较差。虽然初治注射药物的患者不认为给药时间重要,但没有初治患者认为它重要。根据年龄或性别没有观察到明显的差异。患者愿意为“无需准备”剂量支付 83.25 欧元。无初治和初治患者愿意分别支付 34.61 欧元和 14.35 欧元;=0.000,愿意将每日注射改为每周注射。
患者高度重视避免注射,每周给药明显优于每日给药,且降低了治疗的复杂性。这些发现可能有助于更好地了解患者在治疗中偏好和重视的内容,并为临床医生为 2 型糖尿病患者制定治疗决策提供指导。